Insulin glargine

甘精胰岛素

Report date: 2026/03/11 20:02:12

Base Information

Drug NameInsulin glargine
Drug Alias NameInsuline glargine (Sanofi)Insulin glargine U300Insulin U300Insulinum glarginum (Sanofi)Lantus XR +[15] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsHypercholesterolemiaHyperglycemiaDiabetes Mellitus, Type 2 +[14] 
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryUnited States
Original Approved Date2000/04/20
Country/TerritoryCzechiaBulgariaCanada +[41] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofiSanofi-Aventis Deutschland GmbhSanofi-Aventis U.S. Llc +[5] 
Inactive CompaniesUniversity Of MinnesotaHealthpartners InstituteEli Lilly And Company +[6] 
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus +[6] 
Inactive IndicationsHypercholesterolemiaHyperglycemiaDiabetic Ketoacidosis +[8] 

Other Information

ATC CodeA10AE04
Related LinksWikipediaDrugBankKEGG